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Abstract
 
Rheumatoid arthritis (RA) is a heterogeneous syndrome of which a subset of patients develops
vascular inflammation. The genetic determinants that confer risk for rheumatoid vasculitis are
not known, but patients with vascular complications are known to have an expansion of
 
CD4
 
1
 
CD28
 
null
 
 T cells, a cell population potentially involved in endothelial damage.
CD4
 
1
 
CD28
 
null
 
 T cell clones isolated from RA patients with vasculitis were found to express
killer cell immunoglobulin–like receptors (KIRs) with the stimulatory KIR2DS2 often present
in the absence of opposing inhibitory receptors with related specificities. To test the hypothesis
that the KIR2DS2 gene is involved in the development of vasculitis, association studies were
performed. The KIR2DS2 gene was significantly enriched among patients with rheumatoid
 
vasculitis compared with normal individuals (odds ratio 5.56,
 
 P 
 
5
 
 
 
0.001) and patients with RA
but no vasculitis (odds ratio 7.96,
 
 P 
 
5
 
 0.001). Also, the distribution of human histocompatibility
leukocyte antigen (HLA)-C, the putative ligand for KIRs, was significantly different in patients
with rheumatoid vasculitis in comparison with the control populations. These data suggest that
HLA class I–recognizing receptors and HLA class I genes are genetic risk determinants that
modulate the pattern of RA expression. Specifically, KIR2DS2 in conjunction with the appro-
priate HLA-C ligand may have a role in vascular damage by regulating CD4
 
1
 
CD28
 
null
 
 T cells.
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Introduction
 
Rheumatoid arthritis (RA)
 
1 
 
is a chronic destructive joint
disease with crippling potential. Current evidence suggests
that susceptibility to RA is under polygenic control with a
major contribution of the MHC class II locus (1–4). Clini-
cally, the disease is heterogeneous in regard to the progres-
sion of joint destruction, response to treatment, and in-
volvement of extraarticular organs. It has been proposed
that this clinical heterogeneity is genetically determined
and that different disease phenotypes are a reflection of dif-
ferent combinations of disease-risk genes (5). In support of
this concept, MHC class II polymorphisms correlate with
differences in disease pattern and disease aggressiveness.
 
Homozygosity of disease-associated HLA-DRB1
 
*
 
04 alleles
predisposes patients with RA to major organ involvement
such as in Felty’s syndrome and rheumatoid vasculitis (6,
7). A role for sex-linked genes has been inferred because
disease phenotypes in male and female patients can be dis-
tinguished (8). Studies of other possible genetic risk factors
that could function as disease modulators are preliminary
(1, 2, 9, 10); however, biological markers have been identi-
fied that correlate with disease expression and may be gen-
etically determined. In particular, a subset of patients with
RA has expanded populations of CD4 T cells that lack sur-
 
face expression of the CD28 molecule (11). CD4
 
1
 
CD28
 
null
 
T cells are uncommon in healthy individuals. The expan-
sion of this cell subset in patients with RA correlates with
the clinical phenotype of disease; the highest frequencies
are detected in patients with rheumatoid vasculitis (12).
Rheumatoid vasculitis is a life-threatening extraarticular
complication of the rheumatoid syndrome. A direct role of
CD4
 
1
 
CD28
 
null
 
 T cells in vascular injury has been suggested
because these cells are also a risk factor for inflammation
and rupturing of atherosclerotic plaques in acute coronary
syndromes (13, 14).
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Abbreviations used in this paper:
 
 KIR, killer cell Ig–like receptor; RA,
rheumatoid arthritis; RT, reverse transcription. 
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CD4
 
1
 
CD28
 
null
 
 T cells are functionally distinct from clas-
sical CD4 helper T cells. They do not express CD40
ligand, produce large amounts of IFN-
 
g
 
, and express
granzyme B and perforin, giving them the capability to lyse
target cells (15, 16). Their cytotoxic potential, as well as
expression of the NK cell marker CD57, suggests that
CD4
 
1
 
CD28
 
null
 
 T cells share features with NK cells.
The functional activity of NK cells is tightly regulated by
a family of polymorphic receptors that recognize MHC
class I molecules (17, 18). Interaction of human NK cells
with MHC class I molecules is governed by two distinct
receptor families, both of which can transmit inhibitory or
stimulatory signals. CD94/NKG2 receptors are members
of the C-type lectin superfamily and recognize HLA-E
molecules (19, 20). The various allotypes of HLA-A, B,
and C interact with a structurally different set of receptors,
the killer cell Ig-like receptors (KIRs), which belong to the
Ig superfamily (21–23). Different KIR isoforms bind spe-
cific MHC class I allotypes; the KIR2D subfamily has spec-
ificity for HLA-C–encoded molecules (24). MHC class
I–mediated triggering of KIR transduces a dominant in-
hibitory signal that blocks NK cell cytolytic activity and cy-
tokine production in vitro (25). Ligand binding initiates the
phosphorylation of cytoplasmic immunoregulatory tyro-
sine-based inhibitory motifs (ITIMs) with subsequent re-
cruitment of protein tyrosine phosphatases. The MHC-
recognizing receptors of the Ig superfamily also include
members that have truncated cytoplasmic domains lacking
competent ITIMs. These variants have extracellular do-
mains that are highly homologous to the inhibitory recep-
tors and that also appear to bind MHC class I molecules,
but they transmit activation signals (26, 27).
The KIR family is a highly polymorphic multigene fam-
ily of receptors located on chromosome 19q13.4 (28, 29).
Of particular interest, Uhrberg et al
 
.
 
 have described consid-
erable variation of KIR expression among Caucasians (30).
The authors have detected 18 phenotypes in a population
of only 52 individuals. We have, therefore, explored
whether MHC class I–recognizing receptors are expressed
on CD4
 
1
 
CD28
 
null
 
 T cells and whether genetic polymor-
phisms in the KIR family confer susceptibility to rheuma-
toid vasculitis.
 
Materials and Methods
 
Study Population.
 
70 unrelated patients fulfilling the 1988
American College of Rheumatology criteria for RA and with no
major organ involvement (e.g., Felty’s syndrome, interstitial lung
disease, or rheumatoid vasculitis), 30 RA patients with rheuma-
toid vasculitis, and 76 control individuals were enrolled in the
study. This study was approved by the Mayo Clinic Internal Re-
view Board and all participants provided written informed con-
sent. All individuals were Caucasians of Western European de-
scent. The diagnosis of rheumatoid vasculitis was based on
histomorphology or angiogram. Nonhealing lower extremity skin
ulcers without histopathological proof were only accepted as vas-
culitis if there was no clinically evident atherosclerosis. Periungual
nailfold infarcts were not sufficient for the diagnosis of rheuma-
toid vasculitis.
 
Flow Cytometry.
 
Heparinized venous blood was collected and
PBMCs were isolated by density gradient centrifugation over Fi-
coll-Hypaque (Amersham Pharmacia Biotech). Cell surface stain-
ing was performed using combinations of the following antibod-
ies: CD4-peridinin chlorophyll protein (PerCP), CD28-FITC,
CD158a-PE, CD94-FITC (Becton Dickinson), and CD158b-PE
(Beckman Coulter). Samples were analyzed on a FACSCalibur™
flow cytometer (Becton Dickinson) and the frequencies of T cell
subsets were calculated using WinMDI software (Joseph Trotter,
Scripps Research Institute, La Jolla, CA).
 
T Cell Cloning and KIR Phenotyping.
 
CD4
 
1
 
CD28
 
null
 
 T cells
from three RA patients, two healthy individuals, and one patient
with acute coronary syndrome were sorted on a FACS Vantage™
flow cytometer (Becton Dickinson), cloned by limiting dilution
cloning, and the T cell clones were maintained as described (22).
Donors were selected to express KIR2DS2. Total RNA from T
cell clones was extracted using TRIzol reagent (Invitrogen/Life
Technologies). cDNA was amplified with the KIR family mem-
ber–specific primer sets as described by Uhrberg et al
 
.
 
 (30)
 
. 
 
The
nomenclature suggested by E. Long, L. Lanier, and M. Colonna
was used as published in Uhrberg et al
 
.
 
 (30). To confirm clonality,
TCR sequences of selected T cell clones were determined or T
cell clones were subcloned and the KIR pattern was reassessed.
 
KIR and HLA-C Genotyping.
 
Genomic DNA was isolated
using the DNA Isolation Kit for Mammalian Blood (Roche
Molecular Biochemicals/Boehringer) or QIAamp Blood Kit
(QIAGEN). DNA was amplified with KIR2DS1- and KIR2DS2-
specific primers (30) (KIR2DS1, 5
 
9
 
-TCTCCATCAGTCGCAT-
GAA/G-3
 
9
 
, 5
 
9
 
-AGGGCCCAGAGGAAAGTT-3
 
9
 
, and KIR2DS2,
5
 
9
 
-TGCACAGAGAGGGGAAGTA-3
 
9
 
, 5
 
9
 
-CACGCTCTCTC-
CTGCCAA-3
 
9
 
) in 25 
 
m
 
l reaction volume containing 0.525 U
DNA polymerase (Expand High Fidelity PCR System; Roche
Molecular Biochemicals/Boehringer), 0.5 mM dNTPs, 0.2 
 
m
 
M
sense primer, 0.2 
 
m
 
M antisense primer, and 80–300 ng DNA.
PCR was performed in a 9600 thermal cycler (PE Biosystems)
using the following conditions: denaturation at 97
 
8
 
C for 10 min
followed by 5 cycles of 97
 
8
 
C for 20 s, 60
 
8
 
C for 45 s, 72
 
8
 
C for 90 s,
and then 25 cycles of 95
 
8
 
C for 20 s, 58
 
8
 
C for 45 s, and 72
 
8
 
C for
90 s. The amplified products were visualized on ethidium bro-
mide prestained 1% agarose gels.
HLA-C alleles were determined by PCR using the Dynal
HLA-C “low resolution” SSP kit (Dynal) according to the man-
ufacturer’s instructions.
 
Costimulation Experiments.
 
T cell clones that expressed
CD158b by FACS
 
®
 
 and KIR2DS2 but not KIR2DL2 or
KIR2DL3 by PCR were selected. Resting cells (3 
 
3 
 
10
 
5
 
/well)
were incubated with optimal (1 
 
m
 
g/ml) and suboptimal (50 ng/
ml) concentrations of anti-CD3 (Orthoclone OKT3; Ortho Bio-
tech), anti-CD158b (200 ng/ml; GL183; Beckman Coulter), IgG
control (200 ng/ml; ICN Biomedicals), or a combination for 30
min on ice. Bound antibodies were cross-linked with rabbit anti–
mouse IgG (1 
 
m
 
g/ml; ICN Biomedicals) for 18 h at 37
 
8
 
C in the
presence of 1 U/ml recombinant human IL-2 (Proleukin; Chiron
Corp.). Total RNA was isolated using TRIzol (Invitrogen/Life
Technologies) and analyzed for the transcription of IFN-
 
g
 
 se-
quences by reverse transcription (RT)-PCR using the following
primer set: 5
 
9
 
-ACCGAATAATTAGTCAGCTT-3
 
9
 
 and 5
 
9
 
-
ACCTTAAGAAATATTTTAATGC-3
 
9
 
. Transcripts were semi-
quantified on a Light Cycler (Roche Molecular Diagnostics/
Boehringer).
 
Statistical Analysis.
 
The frequencies of specific alleles were
compared between each of the three study groups using two-by-
two tables and either Pearson’s Chi-squared statistic or Fisher’s 
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exact test (for small counts), and the magnitude of effect was esti-
mated by odds ratios and their 95% confidence intervals. The ef-
fects of multiple genes were evaluated simultaneously using logis-
tic regression. All analyses were performed using SAS software.
 
Results
 
KIR Expression on CD4 T Cells from Patients with Rheu-
matoid Vasculitis.
 
MHC class I–recognizing receptors of
the Ig superfamily were detected on CD4 T cells of
patients with RA by flow cytometric analysis. As shown
in Fig. 1, CD4
 
1
 
CD158b
 
1
 
 cells were found exclusively
among CD28
 
null
 
 but not CD28
 
1
 
 cells, indicating the pres-
ence of KIR2DS2, KIR2DL2, and/or KIR2DL3 on the
cell surface. CD4
 
1
 
CD28
 
null
 
 T cells were consistently nega-
tive for the NK cell molecules, CD16 and CD94. CD158a
was infrequently expressed on CD4
 
1
 
CD28
 
null
 
 T cells (data
not shown).
The spectrum of KIR-specific antibodies is limited and
the available antibodies cannot distinguish between stimula-
tory and inhibitory receptors. To analyze the array of KIRs
on CD4
 
1
 
CD28
 
null
 
 T cells, 49 CD4
 
1
 
CD28
 
null
 
 T cell clones
were generated from three patients with rheumatoid vascu-
litis. PCR analysis with primer pairs for six inhibitory KIRs
and five stimulatory KIRs was used to establish KIR expres-
sion patterns. Results are summarized in Fig. 2. Of the acti-
vating receptors, expression of KIR2DS2 was prominent
and ranged from 58–91% of the clones in the three patients
studied. None of the T cell clones expressed transcripts for
KIR2DS1, KIR2DS3, or KIR2DS4; between 0–20% of
 
the clones expressed KIR3DS1. The spectrum of inhibitory
receptors was broader, and all six isoforms were present in
varying frequencies. KIR2DL4 and KIR2DL3 were most
frequently detected. KIR2DL1, KIR2DL2, and KIR3DL2
each appeared more frequently in clones from one patient
whereas KIR3DL1 was rarely found.
This analysis demonstrated that multiple receptors of
the Ig superfamily were simultaneously expressed on
CD4
 
1
 
CD28
 
null
 
 T cell clones. Although the array of KIR
isoforms was broad and several members could appear to-
gether, the expression of stimulatory KIR was more re-
stricted with a clear preference for KIR2DS2. To deter-
mine whether this pattern is generally seen in CD4
 
1
 
CD28
 
null
 
 T cells or whether it is characteristic for rheuma-
toid vasculitis, 53 CD4
 
1
 
CD28
 
null
 
 T cell clones from two
healthy individuals and 28 clones from a patient with an
acute coronary syndrome were analyzed (Fig. 2).
CD4
 
1
 
CD28
 
null
 
 T cells are rarely seen in healthy individuals,
and the two control individuals were, therefore, selected to
have increased frequencies. However, expansion is regularly
observed in acute coronary syndromes to a similar degree as
in rheumatoid vasculitis (13, 14). Only one KIR2DS2
 
1
 
 T
cell clone was found among the 53 clones derived from
the two healthy controls. Of the inhibitory receptors,
KIR2DL4 and KIR3DL2 remained prominent whereas the
frequency of KIR2DL3 expression was slightly lower than
in the patients with RA. The pattern in the patient with
acute coronary syndrome resembled that in patients with
RA in that KIR2DS2 was frequently encountered.
The functional significance of preferential KIR2DS2 ex-
pression should depend on the combination of this stimula-
tory receptor with inhibitory receptors on individual T cell
clones. Because KIR2DS2, KIR2DL2, and KIR2DL3 sup-
posedly recognize related antigens, KIR2DS2
 
1
 
 T cell
clones were analyzed for the coexpression of KIR2DL2
and KIR2DL3. As shown in Fig. 3, KIR2DS2 was most
frequently expressed exclusively (17–54%) or combined
with KIR2DL3 (25–36% of the T cell clones) in the RA
patients. Coexpression of the three receptor isoforms or
combinations with KIR2DL2 were infrequent. These data
demonstrate that in patients with rheumatoid vasculitis,
KIR2DS2 was frequently unopposed by inhibitory recep-
tors of related specificities on CD4
 
1
 
CD28
 
null
 
 T cells. A
similar pattern was seen in the T cell clones from the pa-
tient with an acute coronary syndrome in which 32% of all
clones expressed KIR2DS2 in the absence of KIR2DL3 or
KIR2DL2; in contrast, such clones were not found in the
healthy donors (Fig. 3).
 
KIR2DS2 Is Functional As a Stimulatory Receptor on
CD4
 
1
 
CD28
 
null
 
 T Cells.
 
KIR2DS2 has a short cytoplasmic
domain lacking an immunoreceptor tyrosine-based activa-
tion motif (ITAM) motif and appears to lack intrinsic sig-
naling capability. In NK cells, KIR2DS2 is associated with a
dimeric adapter molecule, DAP12, that is able to recruit the
tyrosine kinases 
 
syk
 
 and ZAP70 and transmit a positive sig-
nal (31, 32). To address whether KIR2DS2 is functional
on CD4
 
1
 
CD28
 
null
 
 T cell clones, clones that expressed
KIR2DS2 in the absence of KIR2DL2 and KIR2DL3 were
Figure 1. CD41CD28null T cells express MHC class I–recognizing re-
ceptors. Peripheral blood CD4 T cells were analyzed by three-color flow
cytometry for the expression of MHC class I–recognizing receptors. A
representative experiment from a patient with rheumatoid vasculitis is
shown. CD158b (encompassing KIR2DS2, KIR2DL2, and KIR2DL3)
was exclusively expressed on CD28null but not on CD281CD41 T cells.
CD158a (KIR2DS1 and KIR2DL1) was infrequently expressed and high
expression of CD94/NKG2 dimers was absent (data not shown). Back-
ground staining with isotype-matched control antibodies is shown as
shaded areas. 
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stimulated with a CD158b-specific antibody (GL183). Re-
sults of an experiment using IFN-g production as the read-
out are shown in Fig. 4. Cross-linking of CD158b in the
absence of CD3 stimulation induces the transcription of
23,153 transcripts of IFN-g mRNA compared with the
constitutive expression of 3,941 copies. If CD158b is cross-
linked in the presence of suboptimal doses of anti-CD3,
transcription of IFN-g is upregulated from 6,628 copies to
63,300 copies. Enhancement of IFN-g production by
costimulation with GL183 was seen in five additional
CD41CD28null T cell clones that constitutively expressed
KIR2DS2 or were transfected with KIR2DS2. Also, cross-
linking with GL183 increased T cell proliferation in re-
sponse to suboptimal anti-CD3 (33, and data not shown).
KIR2DS2 Is a Risk Factor for Rheumatoid Vasculitis.
The preferential expression of KIR2DS2, but not other
stimulatory receptors on CD41CD28null T cells, raised the
possibility that KIR2DS2 is a risk factor for developing vas-
cular inflammation in RA. KIR genes are variably present
in the Caucasian population with the majority of individu-
als typing positive for inhibitory KIR. With the exception
of KIR2DS4, gene representation of activating receptors is
highly variable; 40% of individuals have KIR2DS1 and
40% have KIR2DS2 (30). The genomic presence of the
KIR2DS1 and KIR2DS2 genes was evaluated in 76
healthy control individuals, 70 patients with RA, and 30
patients with unequivocal rheumatoid vasculitis manifest-
ing as ischemic mononeuritis, ischemic ulcerations, or pe-
ripheral gangrene. Results of the genotyping are given in
Table I. Consistent with previous data, 45–47% of the
healthy individuals carried KIR2DS1 or KIR2DS2. Pa-
tients with RA, but without major organ involvement, did
not differ significantly from the control individuals for ei-
ther KIR2DS1 (P 5 0.563) or KIR2DS2 (P 5 0.284). Of
the patients with rheumatoid vasculitis, 50% were positive
for KIR2DS1, similar to the representation of this gene in
control individuals and unselected patients with RA. How-
ever, KIR2DS2 was found in 83% of the cohort with rheu-
matoid vasculitis. The odds ratios for patients with RA vas-
culitis having KIR2DS2 were 5.56 (P 5 0.001, RA
vasculitis versus control) and 7.96 (P 5 0.001, RA vasculi-
tis versus uncomplicated RA; Table II). In contrast, the
odds ratio for unselected RA versus control was 0.70 (P 5
0.284). These data indicated that KIR2DS2 did not affect
the risk of an individual to develop RA but was strongly as-
sociated with the likelihood of vascular complications.
Figure 2. Repertoire of MHC class I–recognizing receptors expressed by CD4 T cells. CD41CD28null T cell clones established from three patients
with rheumatoid vasculitis (top panel) and three controls were characterized for the expression of inhibitory (A) and stimulatory KIR (B) isoforms by
RT-PCR. Two controls were healthy individuals (middle panel), one had an acute coronary syndrome (bottom panel). The expression patterns were not
random but favored the inhibitory KIR2DL4, KIR2DL2, KIR2DL3, and KIR3DL2. Expression of stimulatory receptors was highly restricted to
KIR2DS2 in the patients with RA and the patient with acute coronary syndrome (*not done).1163 Yen et al.
Distribution of HLA-C Alleles in Patients with RA and RA
Vasculitis. Receptors of the KIR2DS subfamily recognize
polymorphisms on HLA-C molecules. Therefore, the func-
tional relevance of KIR2DS receptors depends on the
HLA-C genotype of the patient. To examine whether pa-
tients with rheumatoid vasculitis not only have a skewing in
the genomic representation of KIR genes but also of the
presumptive ligand, we HLA-C genotyped the three study
cohorts (Table III). Compared with ethnically matched
controls, patients without RA vasculitis had a decreased fre-
quency of HLA-C*04 and an increased frequency of HLA-
C*05. The decreased frequency of HLA-C*04 among pa-
tients with RA yielded an odds ratio of 0.39 (P 5 0.024),
and the enrichment of HLA-C*05 gave an odds ratio of
2.92 (P 5 0.024; Table IV). Among patients with RA vas-
culitis, the frequency of HLA-C*04 was even more dimin-
ished (odds ratio 0.21 compared with healthy controls, P 5
0.033) whereas the frequency of HLA-C*05 alleles was in-
creased fourfold (odds ratio 5.71 compared with healthy
controls, P 5 0.001). Two additional findings were unique
for the patients with vasculitis and not observed in the pa-
tients with uncomplicated RA. The representation of
HLA-C*03 was almost doubled, with 60% of patients (cor-
responding to an allele frequency of 33%) typing positive
(odds ratio 3.74, P 5 0.003). Also, 10–13% of the controls
and donors with nonvasculitic RA expressed HLA-C*12
and none of the patients with vasculitis carried that allele;
however, this difference was not statistically significant. Al-
though the findings are based on a large number of compar-
isons, the associations of HLA-C*03 and HLA-C*05 with
vasculitis (contrasted with healthy subjects) remain statisti-
cally significant, even if corrected for the 15 statistical tests
for each of the HLA-C alleles using Bonferroni correction.
Because HLA-C*03 and KIR2DS2 were both more fre-
quent among the patients with vasculitis than the patients
with RA without vasculitis, the independent effect of these
Figure 3. Coexpression of MHC class I–recognizing receptors on CD4
T cell clones. KIR2DS21 T cell clones from Fig. 2 were analyzed for the
coexpression of the inhibitory KIR2DL2 and KIR2DL3 receptors, which
have a highly homologous extracellular domain to KIR2DS2 and which
may recognize the same HLA-C ligands. Approximately one-third of the
clones in the patients with rheumatoid vasculitis or acute coronary syn-
drome (ACS) expressed the stimulatory KIR2DS2 receptor unopposed by
any of these two inhibitory receptors whereas such clones were not found
in the CD41CD28null control T cell clones from the healthy individuals.
Figure 4. Costimulatory function of KIR2DS2. A CD41CD28null T
cell clone that expressed KIR2DS2 but not KIR2DL2 or KIR2DL3 was
unstimulated (A) or stimulated with an optimal concentration of anti-
CD3 (B), suboptimal concentration of anti-CD3 (C), GL183 alone (D), a
suboptimal concentration of anti-CD3 plus control Ig (E), or plus GL183
(F). Cells were harvested after 18 h and transcription of IFN-g was as-
sessed by RT-PCR. Results are representative of three experiments and
are shown in comparison with b-actin transcripts after separation on aga-
rose gels (top panel) or as mean 6 standard deviation of IFN-g transcripts
after semiquantification on a Light Cycler.
Table I. KIR2DS1 and 2DS2 Gene Frequencies Among the 
Study Cohorts
Normal
(n 5 76)
RA
(n 5 70)
RA Vasculitis
(n 5 30)
%% %
KIR2DS1 45 40 50
KIR2DS2 47 39 83
Table II. Odds Ratios for the Association of KIR with 
Disease Phenotype
Comparison
group
Reference
group
Odds ratio
(CI)* P
KIR2DS1 RA Normal 0.82 (0.42 2 1.59) 0.563
KIR2DS2 RA Normal 0.70 (0.36 2 1.35) 0.284
KIR2DS1 RA Vasculitis Normal 1.24 (0.53 2 2.88) 0.624
KIR2DS2 RA Vasculitis Normal 5.56 (1.92 2 16.04) 0.001
KIR2DS1 RA Vasculitis RA 1.50 (0.63 2 3.55) 0.385
KIR2DS2 RA Vasculitis RA 7.96 (2.72 2 23.31) 0.001
*Odds ratio (95% confidence interval [CI]).1164 Killer Cell Immunoglobulin–like Receptor-expressing T Cells in Rheumatoid Arthritis
two genes was evaluated by modeling their risk with logis-
tic regression. After entering both genes into the model,
each demonstrated an independent significant risk associ-
ated with vasculitis (odds ratio for HLA-C*03 5 8.6, P ,
0.001; odds ratio for KIR2DS2 5 3.69, P 5 0.01), sug-
gesting that both contribute a risk to vasculitis, indepen-
dent of each other. We also evaluated whether there was a
significant interaction between these two genes by entering
an interaction term into the logistic regression model, but
this was found not to be statistically significant (P 5 0.483).
However, the limited sample size makes it difficult to rule
out the possibility of interactions.
Discussion
This study demonstrates that a genetic polymorphism
within the family of MHC class I–recognizing receptors is
important in vascular complications of RA. KIR genes en-
code for glycoprotein receptors that bind polymorphic
HLA class I ligands and regulate the activation of NK cells
and a subset of T cells. The diversity in this gene family is
introduced by a minimum of 12 independent loci that are
not universally functional. The diversity is further increased
by alternative RNA splicing and allelic polymorphisms (17,
18, 29). This, in conjunction with receptor–ligand interac-
tions regulating NK cells and selected T cells, raised the
possibility that this family includes candidate genes that
confer susceptibility to developing chronic inflammatory
diseases. Previous data have shown that inhibitory KIR
genes are expressed in the vast majority of individuals and
that the genomic representation of stimulatory receptors is
diverse (30). This study focused on KIR2DS2 and was
guided by the finding that this gene was preferentially ex-
pressed by CD41CD28null T cell clones isolated from pa-
tients with active vasculitis (Figs. 1 and 2). Data presented
demonstrate that the KIR2DS2 gene significantly increases
the risk of patients with RA to develop vasculitic compli-
cations. Also, the distribution of HLA-C alleles, which rep-
resent the presumptive ligand of KIR2DS2, was signifi-
cantly different in patients with rheumatoid vasculitis,
adding further support for the hypothesis that this recep-
tor–ligand pair is involved in the vascular injury occurring
in a subset of patients with RA.
The biological significance of KIR receptors in vivo de-
pends on whether these receptors are expressed in individ-
uals that constitutively express the appropriate ligands.
KIR2D receptors predominantly recognize HLA-C mole-
cules and are able to distinguish between subtle allelic poly-
morphisms (34, 35). Based on their extracellular domains,
the KIR2D receptors have been subsetted into two groups.
Receptors recognized by the antibody GL183 (anti-
CD158b) include the inhibitory receptors, KIR2DL2 and
KIR2DL3, and the stimulatory receptor KIR2DS2. These
receptors recognize HLA-C*01, *03, *07, and *08, all of
which share a serine at position 77 and an asparagine at po-
sition 80 (S77, N80). In contrast, CD158a receptors, in-
cluding KIR2DL1 and KIR2DS1, are specific for HLA-C
alleles that have asparagine at residue 77 and lysine at posi-
tion 80 (N77, K80).
HLA-C genotyping demonstrated a significant difference
in the allelic distribution between patients with RA and
ethnically matched healthy controls. HLA-C*05 was en-
riched and HLA-C*04 was decreased in patients with un-
complicated RA and in patients with rheumatoid vasculitis.
Table III. HLA-C Allele Frequencies Among the Study Cohorts
HLA-C
Normal
(n 5 76)
RA
(n 5 70)
RA vasculitis
(n 5 30)
%% %
*01 5.5 5.1 8.3
*02 3.4 5.8 6.7
*03 17.1 19.6 33.3
*04 13.0 5.8 3.3
*05 4.8 11.6 18.3
*06 6.8 8.7 8.3
*07 32.9 30.4 18.3
*08 3.4 3.6 1.7
*12 6.8 5.1 0
*13 0 0 0
*14 2.1 0.7 0
*15 1.4 0 0
*16 2.1 1.4 1.7
*17 0.7 1.4 0
*18 0 0.7 0
Table IV. Odds Ratios for the Association of HLA-C with 
Disease Phenotype
Comparison
group
Reference
group
Odds ratio
(CI)* P
HLA-C*03 RA Normal 1.13 (0.57 2 2.26) 0.728
HLA-C*04 RA Normal 0.39 (0.16 2 0.95) 0.035
HLA-C*05 RA Normal 2.92 (1.12 2 7.60) 0.024
HLA-C*07 RA Normal 0.95 (0.50 2 1.83) 0.884
HLA-C*03 RA vasculitis Normal 3.74 (1.54 2 9.08) 0.003
HLA-C*04 RA vasculitis Normal 0.21 (0.05 2 0.99) 0.033
HLA-C*05 RA vasculitis Normal 5.71 (1.95 2 16.72) 0.001
HLA-C*07 RA vasculitis Normal 0.45 (0.19 2 1.09) 0.073
HLA-C*03 RA vasculitis RA 3.31 (1.36 2 8.08) 0.007
HLA-C*04 RA vasculitis RA 0.55 (0.11 2 2.78) 0.719
HLA-C*05 RA vasculitis RA 1.95 (0.77 2 4.95) 0.154
HLA-C*07 RA vasculitis RA 0.47 (0.19 2 1.15) 0.096
*Odds ratio (95% confidence interval [CI]).1165 Yen et al.
In contrast, HLA-C*03 was exclusively enriched in the pa-
tients with rheumatoid vasculitis. We excluded linkage dis-
equilibrium with HLA-DRB1*04 as the reason for the en-
richment of HLA-C*03 (data not shown). Enrichment
of CD158b is consistent with the hypothesis that the
KIR2DS2–HLA-C receptor–ligand pair predisposes for
rheumatoid vasculitis. The decrease in HLA-C*04 donors
in the cohort with rheumatoid vasculitis is consistent with
this interpretation. However, the distribution of the re-
maining HLA-C alleles does not follow the pattern that
S77 N80 HLA-C alleles are overrepresented. In particular,
the frequency of HLA-C*05, which expresses N77 K80,
was increased in patients with RA and also patients with
rheumatoid vasculitis. Recent binding studies using soluble
KIR receptors and HLA-C molecules have demonstrated
that the correlation between KIR specificity and HLA-C
polymorphisms is not as strict as initially thought. Winter et
al. have shown that the KIR2DL2, a receptor with an ex-
tracellular domain very homologous to KIR2DS2, binds to
the N77 K80 HLA-C*1503 allele with the same affinity as
to HLA-C*01 and HLA-C*03 (36). Also, stimulatory re-
ceptors, including KIR2DS2, had very low affinity for
their presumptive HLA-C ligand, a finding that was attrib-
uted to a substitution of tyrosine for phenylalanine at posi-
tion 45 (36, 37). We have sequenced KIR2DS2 genes from
RA vasculitis patients and have found no allelic polymor-
phisms, excluding that a sequence variation could influence
the specificity profile (data not shown).
Alternatively, peptides bound in the groove of HLA-C
alleles could modify the recognition pattern of KIR recep-
tors. This has been elegantly shown for the CD94/NKG2
family of NK receptors that recognize the HLA-E mole-
cule (38). HLA-E binds peptides derived from the signal
sequences of certain HLA molecules that have limited se-
quence polymorphism (39). These polymorphisms influ-
ence the affinity of receptor–HLA-E interactions and the
functional activity of the NK cell. In analogy, recognition
of HLA-C molecules by KIR may also be influenced by
the composition of the peptides bound in the MHC
groove. Several reports have indicated that amino acid po-
sitions 7 and 8 of the peptide are important and could in-
fluence the binding of KIR (40, 41). It has been argued
that variability in the peptides bound is not important for
the biological function of inhibitory receptor because most
peptides are permissive for recognition. Triggering of the
inhibitory KIR would occur even if few nonpermissive
peptides are bound (17). However, the concept is attractive
for stimulatory KIRs that recognize the dominant HLA-C
self-peptide complexes with very low affinity but may bind
selected HLA-C peptide complexes with higher affinities.
KIR2DS2 is expressed on NK cells and on some CD4
and CD8 T cells. The association of KIR2DS2 with rheu-
matoid vasculitis could reflect a functional activity of any of
these cell populations that is important in the pathogenetic
events inducing vascular damage. However, there is cir-
cumstantial evidence to implicate CD41CD28null T cells.
This population of cells is distinctly infrequent in the ma-
jority of healthy individuals, but is expanded in a subset of
patients with RA (11). Patients with increased frequencies
of CD41CD28null T cells have increased risk of developing
extraarticular manifestations, including subcutaneous nod-
ule formation and rheumatoid vasculitis (12). Nodule for-
mation is seen in about 30% of patients with RA and repre-
sents a granulomatous reaction after a vascular injury.
Rheumatoid vasculitis is a serious condition involving
inflammation of mid-size and large arteries. Expanded
CD41CD28null T cells have also been associated with other
inflammatory vasculopathies such as Wegener’s granuloma-
tosis and acute coronary syndromes (13, 14, 42). An acute
coronary syndrome evolves if inflammation of an athero-
sclerotic plaque leads to plaque rupture, subsequent throm-
bosis, and myocardial ischemia (43, 44). Patients with in-
creased frequencies of CD41CD28null T cells and coronary
artery disease have an increased risk of developing acute
coronary syndromes. In these patients, clonally expanded
CD41CD28null T cells can be demonstrated in the ruptured
plaque, suggesting that these cells drive the plaque inflam-
mation that leads to rupture.
CD41CD28null but not CD41CD281 T cells express
KIR; it was the preferential expression of the CD158b
molecule on these cells and the frequent finding of
KIR2DS21CD41CD28null T cell clones in rheumatoid
vasculitis that led to this study design. The three patients
with rheumatoid vasculitis expressed KIR2DS2 on 58–91%
of their T cell clones. In contrast, KIR2DS2 expression was
very infrequent on CD4 T cell clones from two normal in-
dividuals (0 and 3%), although both of them were selected
to carry the KIR2DS2 gene and to have an expanded
CD41CD28null T cell compartment comparable to the pa-
tients with rheumatoid vasculitis. Of interest, the third se-
lected control patient had an acute coronary event, a dis-
ease that has also been correlated with an expansion of
CD41CD28null T cells (13). T cell clones from this patient
exhibited a very similar KIR expression pattern as the pa-
tients with RA, suggesting that stimulatory KIRs may not
only be risk factors for rheumatoid vasculitis but also for
other vascular diseases that are associated with increased
CD41CD28null T cell frequencies.
How could KIR2DS2-expressing cells be involved in
the disease process? The function of stimulatory KIRs is
unclear. In particular, these receptors are usually expressed
in the context of several inhibitory receptors. In addition, it
has been debated whether these receptors are at all func-
tional in T cells that may lack the necessary adapter mole-
cules. For the CD41CD28null T cell clones described here,
we were able to demonstrate a costimulatory activity of
CD158b-specific antibodies to enhance proliferation and
cytokine production (33; Fig. 4), confirming earlier reports
that KIR2DS2 can function as a costimulatory molecule in
response to suboptimal TCR triggering (45, 46). Further
evidence for a unique role of KIR1CD41 T cells comes
from the observation that in the patients with rheumatoid
vasculitis and in the patient with an acute coronary syn-
drome, CD41CD28null T cells expressed KIR2DS2 in the
absence of opposing inhibitory receptors of the same speci-
ficity. Thus, in CD41CD28null T cells, KIR may be impor-1166 Killer Cell Immunoglobulin–like Receptor-expressing T Cells in Rheumatoid Arthritis
tant in the regulation of peripheral tolerance, and the activ-
ity of KIR2DS2 may favor the activation of autoreactive T
cells. It can easily be envisioned that such a mechanism
is important in autoimmune inflammation. However,
KIR2DS2 is not a risk factor for the synovial inflammation
of RA, suggesting that this putative costimulatory function
is not critical for synovitis. The association of KIR2DS2
with vascular complications implicates such a costimulatory
activity in the interaction between endothelial cells and
immune cells. This may be of particular relevance for
CD41CD28null T cells, which have been shown to be au-
toreactive and are no longer under the control of the
CD28–CD80/CD86 interaction (11).
In summary, we have provided evidence for the model
that genetic risk factors determine variations in clinical
phenotypes of an autoimmune disease such as RA. Our
data are the first to implicate the recently described poly-
morphisms in MHC class I–recognizing receptors in the
pathogenesis of a chronic inflammatory disease. Identifying
and understanding risk factors for extraarticular disease in
RA is of clinical relevance because of the high morbidity
and increased mortality associated with this complication.
However, the findings may have implications beyond RA.
CD41CD28null T cells carrying MHC class I–recognizing
receptors contribute to vascular inflammation in an array of
diseases ranging from Wegener’s granulomatosis and rheu-
matoid vasculitis to life-threatening acute ischemia in coro-
nary artery disease. It remains to be seen whether the ability
of CD41CD28null T cells to inflict endothelial injury and to
cause vascular damage is generally linked to genetic poly-
morphisms of the KIR family and their MHC class I
ligands.
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